Patient-reported outcomes (PROs) (i.e. any information on the status, health condition, health-related behaviour or healthcare experiences directly assessed and reported by the patient, without the response being interpreted by a clinician or a third party) [ 1 FDA U.S. Food and Drug Administration (FDA) Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual. Life Outcomes.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by O. Mir
Essential digital health
The digital solutions offered to healthcare providers are rapidly expanding and a number of scientific journals have reported the results of studies in favour of the adoption of telemedicine. The Sars-Cov-2 pandemic has required professionals, as well as patients, to adapt in order to limit travel and hospital visits.
Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment
Background Hepatitis B virus (HBV) reactivation is a well-known risk during chemotherapy for hematological malignancies with reported rates ranging between 14% and 72%. However, there is a paucity of data regarding HBV infection management and reactivation risk in patients receiving systemic treatments for solid tumors. Design We conducted a PubMed search for publications from January 1990 until May 2016 related to HBV reactivation.
Update of the T-DIS randomized phase II trial: Trabectedin rechallenge versus continuation in patients (pts) with advanced soft tissue sarcoma (ASTS)
Background: Trabectedin (T) maintenance beyond 6 cycles (cy) of treatment in responding pts with ASTS is associated with improved progression-free survival (PFS) vs T discontinuation (Le Cesne, Lancet Oncol 2015). The impact of T rechallenge after progressive disease (PD) was prospectively analyzed by the French Sarcoma Group in the national randomized phase II trial (T-DIS; NCT01303094).
Predictive factors for toxicity and survival of second line sunitinib in advanced gastrointestinal stromal tumours (GIST)
Background: Sunitinib is standard second-line treatment in advanced GIST. Predictive factors for grade 3-4 toxicity, progression-free survival (PFS) and overall survival (OS) for patients treated outside clinical studies, but in sarcoma reference centers, are not well defined. Demographic and clinical features, tumour characteristics and biological parameters were investigated.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with O.
Contact O., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack